← All trials
NCT05021640
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2021
- Primary completion
- Sep 10, 2022
- Completion date
- Sep 10, 2022
- First posted
- Aug 25, 2021
- Last posted
- Nov 8, 2021
- Enrollment
- 36
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dicerna Pharmaceuticals, Inc.Lead sponsor
- ParexelOverall official - principal investigator
- ParexelCollaborator
- Dicerna Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.